Current state and future prospects of direct-to-consumer pharmacogenetics

Frontiers in Pharmacology

Volumn 3 AUG, Issue , 2012, Pages

  Chua, E W ^a,b   Kennedy, M A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Direct to consumer; Personal genome; Personalized medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ARTICLE; ETHNICITY; GENE SEQUENCE; GENETIC SCREENING; GENETIC SERVICE; GENOME ANALYSIS; GENOTYPE; HEALTH CARE DELIVERY; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS;

EID: 84866156660     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00152     Document Type: Article

References (33)

1. 23andMe. (2011). Exome 80x [Online]. San Francisco. Available at: https://www.23andme.com/exome/ [accessed 30 January 2012].
2. Anonymous. (2008). Direct-to-consumer genetic tests: flawed and unethical. Lancet Oncol. 9, 1113.
3. Altman, R. B. (2011). Pharmacoge-nomics:"noninferiority" is sufficient for initial implementation. Clin. Pharmacol. Ther. 89, 348-350.
4. Black, J. L., Walker, D. L., O'kane, D. J., and Harmandayan, M. (2012). Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab. Dispos. 40, 111-119.
5. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y., and Chen, Y. T. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486-486.
6. de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., and Goldstein, J. A. (1994). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422.
7. Dvoskin, R. (2011). GPPC Releases Updated List of DTC Genetic Testing Companies [Online]. Genetics and Public Policy Center. Available at: http://www.dnapolicy. org/news.release.php?action=detail& pressrelease_id=145 [accessed 26 January 2012].
8. Ferguson, R. J., De Morais, S. M. F., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G. R., Sarich, T. C., Wright, J. M., Dayer, P., and Goldstein, J. A. (1998). A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284, 356-361.
9. Frueh, F. W., Greely, H. T., Green, R. C., Hogarth, S., and Siegel, S. (2011). The future of direct-to-consumer clinical genetic tests. Nat. Rev. Genet. 12, 511-515.
10. Gaedigk, A., Ndjountche, L., Divakaran, K., Dianne Bradford, L., Zineh, I., Oberlander, T. F., Brousseau, D. C., Mccarver, D. G., Johnson, J. A., Alander, S. W., Wayne Riggs, K., and Steven Leeder, J. (2007a). Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81, 242-251.
11. Gaedigk, A., Simon, S. D., Pearce, R. E., Bradford, L. D., Kennedy, M. J., and Leeder, J. S. (2007b). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242.
12. Hauskeller, C. (2011). Direct-to-consumer genetic testing. BMJ 342, d2317.
13. Ibeanu, G. C., Blaisdell, J., Ghanayem, B I., Beyeler, C., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., Daly, A. K., and Goldstein, J. A. (1998). An additional defec tive allele, CYP2C19*5, contributes to the S-mephenytoin poor metabo-lizer phenotype in Caucasians. Phar-macogenet. Genom. 8, 129-136.
14. Ito, K., Higami, K., Masaki, N., Sugiyama, M., Mukaide, M., Saito, H., Aoki, Y., Sato, Y., Imamura, M., Murata, K., Nomura, H., Hige, S., Adachi, H., Hino, K., Yat-suhashi, H., Orito, E., Kani, S., Tanaka, Y., and Mizokami, M. (2011). The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J. Clin. Microbiol. 49, 1853-1860.
15. Kirchheiner, J. (2008). CYP2D6 phe-notype prediction from genotype: which system is the best? Clin. Pharmacol. Ther. 83, 225-227.
16. Lange, C. M., and Zeuzem, S. (2011). IL28B single nucleotide polymorphisms in the treatment of hepatitis C.J. Hepatol. 55, 692-701.
17. Lenzer, J., and Brownlee, S. (2008). Knowing me, knowing you. BMJ 336, 858-860.
18. Lötsch, J., Rohrbacher, M., Schmidt, H., Doehring, A., Brockmöller, J., and Geisslinger, G. (2009). Can extremely lowor high morphine formation from codeine be predicted prior to therapy initiation? Pain 144, 119-124.
19. McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūte, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., De Bakker, P. I. W., Chinthapalli, K., Molokhia, M., Johnson, M. R., O'connor, G. D., Chaila, E., Alhusaini, S., Shianna, K. V., Radtke, R. A., Heinzen, E. L., Walley, N., Pandolfo, M., Pichler, W., Park, B. K., Depondt, C., Sisodiya, S. M., Goldstein, D. B., Deloukas, P., Delanty, N., Cavalleri, G. L., and Pirmohamed, M. (2011). HLA-A*3101 and carbamazepine-induced hyper-sensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143.
20. Mcguire, A. L., Cho, M. K., Mcguire, S. E., and Caulfield, T. (2007). The future of personal genomics. Science 317, 1687.
21. Nelson, M. R., Wegmann, D., Ehm, M. G., Kessner, D., St Jean, P., Verzilli, C., Shen, J., Tang, Z., Bacanu, S. A., Fraser, D., Warren, L., Aponte, J., Zawistowski, M., Liu, X., Zhang, H., Zhang, Y., Li, J., Li, Y., Li, L., Woollard, P., Topp, S., Hall, M. D., Nangle, K., Wang, J., Abecasis, G., Cardon, L. R., Zollner, S., Whittaker, J. C., Chissoe, S. L., Novembre, J., and Mooser, V. (2012). An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337, 100-104.
22. Ng, P. C., Murray, S. S., Levy, S., and Venter, J. C. (2009). An agenda for personalized medicine. Nature 461, 724-726.
23. PharmGKB. (2011). Haplotype CYP2C19*3A [Online]. Pharma-cogenomics Knowledge Base. Available at: http://www.pharmgkb.org/haplotype/PA165945748 [accessed 2 January 2012].
24. PharmGKB. (2012). Drug labels [Online]. Pharmacogenomics Knowledge Base. Available at: http://www.pharmgkb.org/search/labelList.action [accessed 30 January 2012].
25. Platt, D. (2009). When consumers get their genomes. Pers. Med. 6, 669-679.
26. Relling, M. V., and Klein, T. E. (2011). CPIC: clinical pharmacoge-netics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89, 464-467.
27. Sim, S. C. (2011). CYP2C19 Allele Nomenclature [Online]. Available at: http://www.cypalleles.ki.se/cyp2c19. htm [accessed 2 February 2012].
28. Spencer, D. H., Lockwood, C., Topol, E., Evans, J. P., Green, R. C., Mansfield, E., and Tezak, Z. (2011). Direct-to-consumer genetic testing: reliable or risky? Clin. Chem. 57, 1641-1644.
29. Stanek, E. J., Sanders, C. L., Taber, K. A., Khalid, M., Patel, A., Ver-brugge, R. R., Agatep, B. C., Aubert, R. E., Epstein, R. S., and Frueh, F. W. (2012). Adoption of pharma-cogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450-458.
30. Swen, J. J., Nijenhuis, M., De Boer, A., Grandia, L., Maitland-Van Der Zee, A. H., Mulder, H., Rongen, G. A., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., Van Der Weide, J., Wilffert, B., Deneer, V. H. M., and Guchelaar, H. J. (2011). Pharmaco-genetics: from bench to byte - an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673.
31. US Food and Drug Administration (FDA). (2012). Table of Pharmacoge-nomic Biomarkers in Drug Labels [Online]. FDA. Available at: http:// www.fda.gov/drugs/scienceresearch/ researchareas/pharmacogenetics/ucm 083378.htm [accessed 26 January 2012].
32. Vashlishan Murray, A. B., Carson, M. J., Morris, C. A., and Beckwith, J. (2010). Illusions of scientific legitimacy: misrepresented science in the direct-to-consumer genetic-testing marketplace. Trends Genet. 26, 459-461.
33. Zhang, D., Qian, Y., Akula, N., Alliey-Rodriguez, N., Tang, J., Ger-shon, E. S., and Liu, C. (2011). Accuracy of CNV detection from GWAS data. PLoS ONE 6, e14511. doi:10.1371/journal.pone.0014511